AIM: To analyze the influence of human immunodeficiency virus (HIV) infection on the course of hepatitis C virus (HCV) infection. METHODS: We performed a meta-analysis to quantify the effect of HIV co-infection on progressive liver disease in patients with HCV infection. Published studies in the English or Chinese-language medical literature involving cohorts of HIV-negative and -positive patients coinfected with HCV were obtained by searching the PUBMED, EMBASE and CBM. Data were extracted independently from relevant studies by 2 investigators and used in a fixed-effect meta analysis to determine the difference in the course of HCV infection in the 2 groups. RESULTS: Twenty-nine trails involving 16750 patients were identified including the outcome of histological fibrosis or cirrhosis or de-compensated liver disease or hepatocellular carcinoma or death. These studies yielded a combined adjusted odds ratio (OR) of 3.40 [95% confidence interval (CI) = 2.45 and 4.73]. Of note, studies that examined histological fibrosis/cirrhosis, decompensated liver disease, hepatocellular carcinoma or death had a pooled OR of 1.47 (95% CI = 1.27 and 1.70), 5.45 (95% CI = 2.54 and 11.71), 0.76 (95% CI = 0.50 and 1.14), and 3.60 (95% CI = 3.12 and 4.15), respectively. CONCLUSION: Without highly active antiretroviral therapies (HAART), HIV accelerates HCV disease progression, including death, histological fibrosis/cirrhosis and decompensated liver disease. However, the rate of hepatocellular carcinoma is similar in persons who had HCV infection and were positive for HIV or negative for HIV.
AIM: To analyze the influence of human immunodeficiency virus (HIV) infection on the course of hepatitis C virus (HCV) infection. METHODS: We performed a meta-analysis to quantify the effect of HIV co-infection on progressive liver disease in patients with HCV infection. Published studies in the English or Chinese-language medical literature involving cohorts of HIV-negative and -positive patients coinfected with HCV were obtained by searching the PUBMED, EMBASE and CBM. Data were extracted independently from relevant studies by 2 investigators and used in a fixed-effect meta analysis to determine the difference in the course of HCV infection in the 2 groups. RESULTS: Twenty-nine trails involving 16750 patients were identified including the outcome of histological fibrosis or cirrhosis or de-compensated liver disease or hepatocellular carcinoma or death. These studies yielded a combined adjusted odds ratio (OR) of 3.40 [95% confidence interval (CI) = 2.45 and 4.73]. Of note, studies that examined histological fibrosis/cirrhosis, decompensated liver disease, hepatocellular carcinoma or death had a pooled OR of 1.47 (95% CI = 1.27 and 1.70), 5.45 (95% CI = 2.54 and 11.71), 0.76 (95% CI = 0.50 and 1.14), and 3.60 (95% CI = 3.12 and 4.15), respectively. CONCLUSION: Without highly active antiretroviral therapies (HAART), HIV accelerates HCV disease progression, including death, histological fibrosis/cirrhosis and decompensated liver disease. However, the rate of hepatocellular carcinoma is similar in persons who had HCV infection and were positive for HIV or negative for HIV.
Authors: Jennifer R Kramer; Thomas P Giordano; Julianne Souchek; Peter Richardson; Lu-Yu Hwang; Hashem B El-Serag Journal: Am J Gastroenterol Date: 2005-01 Impact factor: 10.864
Authors: Cristiane Valle Tovo; Angelo Alves de Mattos; Andréa Ribeiro de Souza; Juliana Ferrari de Oliveira Rigo; Paulo Roberto Lerias de Almeida; Bruno Galperim; Breno Riegel Santos Journal: Liver Int Date: 2007-02 Impact factor: 5.828
Authors: B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen Journal: J Hepatol Date: 1997-01 Impact factor: 25.083
Authors: Juan A Pineda; Manuel Romero-Gómez; Fernando Díaz-García; José A Girón-González; José L Montero; Julián Torre-Cisneros; Raúl J Andrade; Mercedes González-Serrano; José Aguilar; Manuela Aguilar-Guisado; José M Navarro; Javier Salmerón; Francisco J Caballero-Granado; José A García-García Journal: Hepatology Date: 2005-04 Impact factor: 17.425
Authors: F Tradati; M Colombo; P M Mannucci; M G Rumi; C De Fazio; G Gamba; N Ciavarella; A Rocino; M Morfini; A Scaraggi; E Taioli Journal: Blood Date: 1998-02-15 Impact factor: 22.113
Authors: Colette Smit; Charlotte van den Berg; Ronald Geskus; Ben Berkhout; Roel Coutinho; Maria Prins Journal: J Acquir Immune Defic Syndr Date: 2008-02-01 Impact factor: 3.731
Authors: Valentina Li Vecchi; Maurizio Soresi; Claudia Colomba; Giovanni Mazzola; Pietro Colletti; Maurizio Mineo; Paola Di Carlo; Emanuele La Spada; Giovanni Vizzini; Giuseppe Montalto Journal: World J Gastroenterol Date: 2010-11-07 Impact factor: 5.742
Authors: B P Linas; B Wang; M Smurzynski; E Losina; R J Bosch; B R Schackman; J Rong; P E Sax; R P Walensky; J Schouten; K A Freedberg Journal: J Viral Hepat Date: 2010-06-09 Impact factor: 3.728
Authors: Siddharth A Mahure; Joseph A Bosco; James D Slover; Jonathan Vigdorchik; Richard Iorio; Ran Schwarzkopf Journal: Clin Orthop Relat Res Date: 2018-02 Impact factor: 4.176
Authors: Lisa R C Saud; Aline L Chagas; Claudia Maccali; Paulo V A Pinto; Natally Horvat; Regiane S S M Alencar; Claudia M Tani; Edson Abdala; Flair J Carrilho Journal: Eur J Gastroenterol Hepatol Date: 2021-04-01 Impact factor: 2.586